Multicenter Evaluation of the FilmArray Blood Culture Identification 2 Panel for Pathogen Detection in Bloodstream Infections.

BCID2 BSI Biofire FilmArray bloodstream infection genotypic identification molecular diagnosis rapid diagnosis resistance gene sepsis

Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
14 02 2023
Historique:
pubmed: 16 12 2022
medline: 17 2 2023
entrez: 15 12 2022
Statut: ppublish

Résumé

The FilmArray Blood Culture Identification 2 panel (BCID2; bioMérieux) is a fully automated PCR-based assay for identifying bacteria, fungi, and bacterial resistance markers in positive blood cultures (BC) in about 1 h. In this multicenter study, we evaluated the performance of the BCID2 panel for pathogen detection in positive BC. Conventional culture and BCID2 were performed in parallel at four tertiary-care hospitals. We included 152 positive BC-130 monomicrobial and 22 polymicrobial cultures-in this analysis. The BCID2 assay correctly identified 90% (88/98) of Gram-negative and 89% (70/79) of Gram-positive bacteria. Five bacterial isolates targeted by the BCID2 panel and recovered from five positive BC, including three polymicrobial cultures, were missed by the BCID2 assay. Fifteen isolates were off-panel organisms, accounting for 8% (15/182) of the isolates obtained from BC. The mean positive percent agreement between the BCID2 assay and standard culture was 97% (95% confidence interval, 95 to 99%), with agreement ranging from 67% for Candida albicans to 100% for 17 targets included in the BCID2 panel. BCID2 also identified the

Identifiants

pubmed: 36519852
doi: 10.1128/spectrum.02547-22
pmc: PMC9927563
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0254722

Références

PLoS One. 2019 Sep 26;14(9):e0223122
pubmed: 31557233
J Clin Microbiol. 2021 Jul 19;59(8):e0054321
pubmed: 33980648
Clin Microbiol Infect. 2013 Jun;19(6):501-9
pubmed: 23473333
J Clin Microbiol. 2018 Nov 27;56(12):
pubmed: 30135230
Clin Microbiol Rev. 2014 Oct;27(4):647-64
pubmed: 25278570
J Clin Microbiol. 2014 Dec;52(12):4368-71
pubmed: 25274998
J Clin Microbiol. 2016 Mar;54(3):576-84
pubmed: 26677254
J Antimicrob Chemother. 2018 Mar 1;73(suppl_4):iv2-iv5
pubmed: 29608754
Expert Rev Mol Diagn. 2019 Feb;19(2):161-173
pubmed: 30640566
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 27956424
Intensive Care Med. 2021 Nov;47(11):1181-1247
pubmed: 34599691
Clin Microbiol Rev. 2012 Jul;25(3):450-70
pubmed: 22763634
J Antimicrob Chemother. 2007 Oct;60(4):855-63
pubmed: 17644532
Emerg Infect Dis. 2021 Jul;27(7):1840-1849
pubmed: 34153220
Ann Intern Med. 2019 Jun 18;170(12):845-852
pubmed: 31083728
Clin Microbiol Infect. 2020 Feb;26(2):142-150
pubmed: 31760113
Diagn Microbiol Infect Dis. 2012 Dec;74(4):349-55
pubmed: 22999332
J Med Microbiol. 2018 Sep;67(9):1294-1301
pubmed: 30051799
J Clin Microbiol. 2016 Mar;54(3):687-98
pubmed: 26739158
Diagn Microbiol Infect Dis. 2015 Feb;81(2):96-101
pubmed: 25488272
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Microbiol Spectr. 2021 Sep 3;9(1):e0042921
pubmed: 34431685
Clin Microbiol Infect. 2018 Sep;24(9):935-943
pubmed: 29605563
J Clin Microbiol. 2017 Dec;55(12):3328-3338
pubmed: 28855303
Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):487-96
pubmed: 25311986
N Engl J Med. 2017 Jun 8;376(23):2235-2244
pubmed: 28528569
J Clin Microbiol. 2019 Mar 28;57(4):
pubmed: 30651387
Pathology. 2021 Dec;53(7):889-895
pubmed: 34120744
Intensive Care Med. 2020 Feb;46(2):266-284
pubmed: 32047941
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33472903
Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):363-371
pubmed: 34350523
Clin Infect Dis. 2021 Sep 15;73(6):1103-1106
pubmed: 33772269
BMC Infect Dis. 2020 Feb 14;20(1):142
pubmed: 32059701
Clin Infect Dis. 2015 Oct 1;61(7):1071-80
pubmed: 26197846
J Clin Microbiol. 2019 Jan 30;57(2):
pubmed: 30487304
Diagn Microbiol Infect Dis. 2016 Sep;86(1):118-20
pubmed: 27342782

Auteurs

François Caméléna (F)

Département de Bactériologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.
Université Paris Cité and Université Sorbonne Paris Nord, INSERM, IAME, Paris, France.

Gauthier Péan de Ponfilly (G)

Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France.
Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France.

Hélène Pailhoriès (H)

Laboratoire de Bactériologie, Institut de Biologie en Santé, Centre Hospitalier Universitaire d'Angers, Laboratoire HIFIH, UPRES EA3859, SFR ICAT 4208, Université d'Angers, Angers, France.

Lucas Bonzon (L)

Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Montpellier et MIVEGEC, UMR IRD-CNRS-Université de Montpellier, Montpellier, France.

Alexandre Alanio (A)

Laboratoire de Parasitologie-Mycologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.
Institut Pasteur, Université Paris Cité, CNRS, Unité de Mycologie Moléculaire, UMR2000, Paris, France.

Thibaut Poncin (T)

Département de Bactériologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.
Université Paris Cité and Université Sorbonne Paris Nord, INSERM, IAME, Paris, France.

Matthieu Lafaurie (M)

Département des Maladies Infectieuses et Tropicales, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.

François Dépret (F)

Département d'Anesthésie et Réanimation chirurgicale et brûlés, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.

Emmanuel Cambau (E)

Université Paris Cité and Université Sorbonne Paris Nord, INSERM, IAME, Paris, France.
Laboratoire de mycobactériologie spécialisée et de référence, Laboratoire associé du Centre National de Référence des mycobactéries et résistance des mycobactéries aux antituberculeux, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.

Sylvain Godreuil (S)

Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Montpellier et MIVEGEC, UMR IRD-CNRS-Université de Montpellier, Montpellier, France.

Rachel Chenouard (R)

Laboratoire de Bactériologie, Institut de Biologie en Santé, Centre Hospitalier Universitaire d'Angers, Laboratoire HIFIH, UPRES EA3859, SFR ICAT 4208, Université d'Angers, Angers, France.

Alban Le Monnier (A)

Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France.
Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France.

Hervé Jacquier (H)

Département de Bactériologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.
Université Paris Cité and Université Sorbonne Paris Nord, INSERM, IAME, Paris, France.

Béatrice Berçot (B)

Département de Bactériologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris, Paris, France.
Université Paris Cité and Université Sorbonne Paris Nord, INSERM, IAME, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH